THIS IS A DEVELOPMENT VERSION OF PROFILES. PLEASE GO TO THE PRODUCTION ENVIRONMENT FOR UPDATES

Header Logo

Connection

Shailendra Dwivedi to Antineoplastic Agents

This is a "connection" page, showing publications Shailendra Dwivedi has written about Antineoplastic Agents.
Connection Strength

0.485
  1. Inhibition of BMI1, a Therapeutic Approach in Endometrial Cancer. Mol Cancer Ther. 2018 10; 17(10):2136-2143.
    View in: PubMed
    Score: 0.103
  2. MDR1 mediated chemoresistance: BMI1 and TIP60 in action. Biochim Biophys Acta. 2016 08; 1859(8):983-93.
    View in: PubMed
    Score: 0.089
  3. Amino acids derived benzoxazepines: design, synthesis and antitumor activity. Bioorg Med Chem Lett. 2013 Dec 15; 23(24):6816-21.
    View in: PubMed
    Score: 0.074
  4. Specific targeting of insulin-like growth factor 1 receptor signaling in human estrogen dependent breast cancer cell by a novel tyrosine-based benzoxazepine derivative. Mol Cell Endocrinol. 2011 May 16; 338(1-2):68-78.
    View in: PubMed
    Score: 0.062
  5. Anti-tumor activity of a new series of benzoxazepine derivatives in breast cancer. Bioorg Med Chem Lett. 2010 Jan 01; 20(1):283-7.
    View in: PubMed
    Score: 0.056
  6. Synthesis and biological evaluation of 3,4,6-triaryl-2-pyranones as a potential new class of anti-breast cancer agents. Bioorg Med Chem. 2009 Jun 01; 17(11):3847-56.
    View in: PubMed
    Score: 0.054
  7. Evaluating the Mechanism and Therapeutic Potential of PTC-028, a Novel Inhibitor of BMI-1 Function in Ovarian Cancer. Mol Cancer Ther. 2018 01; 17(1):39-49.
    View in: PubMed
    Score: 0.024
  8. MICU1 drives glycolysis and chemoresistance in ovarian cancer. Nat Commun. 2017 05 22; 8:14634.
    View in: PubMed
    Score: 0.024
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

THIS IS A DEVELOPMENT VERSION OF PROFILES. PLEASE GO TO THE PRODUCTION ENVIRONMENT FOR UPDATES